GlassScriptPhysician profile
Jackelin Smith
NPI 1083175871
$3,987.97
in general payments reported to CMS, 2019-2025
24 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $452 · 2023: $460 · 2024: $1,409 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,042.41 | 2021-2025 | Nuzyra |
| Insmed, INC. | $464.01 | 2021-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $434.45 | 2022-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Aimmune Therapeutics, INC. | $310.43 | 2024-2025 | Zenpep, Vowst |
| Shionogi INC | $243.57 | 2021-2025 | Fetroja |
| Neurocrine Biosciences, INC. | $137.68 | 2024 | Ingrezza |
| Abbvie INC. | $124.91 | 2021-2022 | |
| Eisai INC. | $122.07 | 2024 | |
| Novo Nordisk INC | $119.92 | 2025 | Ozempic |
| Ferring Pharmaceuticals INC. | $115.10 | 2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $109.06 | 2025 | Hyqvia, Cuvitru |
| Pfizer INC. | $99.63 | 2025 | |
| Axsome Therapeutics, INC. | $97.15 | 2024 | Auvelity |
| Amgen INC. | $91.72 | 2024 | Repatha |
| United Therapeutics Corporation | $85.60 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $84.67 | 2025 | Dovato |
| Sanofi-Aventis U.S. LLC | $81.18 | 2024 | |
| Merck Sharp & Dohme LLC | $59.31 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Gilead Sciences, INC. | $37.93 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $30.52 | 2025 | |
| Csl Behring | $29.62 | 2025 | Hizentra |
| Kci USA, INC. | $25.29 | 2022 | |
| La Jolla Pharmaceutical Company | $21.79 | 2022 | |
| Convatec INC. | $19.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackelin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.